PTSD and Sleep Medications After a Personal Injury: Rexulti, Quviviq, and Dayvigo

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | October 6, 2025 | 10 min read

Personal injury accidents are a leading cause of PTSD, and the sleep disruption that follows trauma is both clinically significant and highly documentable. Rexulti (brexpiprazole), Quviviq (daridorexant), and Dayvigo (lemborexant) are three brand-name medications addressing the psychological and sleep sequelae of injury — a dimension of PI treatment that is frequently underrecognized and underdocumented.

PTSD and Sleep Medications After a Personal Injury: Rexulti, Quviviq, and Dayvigo

When attorneys and adjusters think about personal injury medication, the focus is typically on pain — analgesics, muscle relaxants, anti-inflammatories. The psychological and sleep sequelae of trauma are often underappreciated, yet they are common, clinically documented, and increasingly treated with targeted brand-name medications that belong in any comprehensive PI lien.

Motor vehicle accidents are the most common cause of PTSD in the general population. Sleep disruption is virtually universal in patients with significant physical pain. Both conditions interact with and worsen the pain itself, creating clinical pictures that require psychiatric and sleep-focused pharmacological treatment alongside the purely physical injury management.

PTSD After a Personal Injury Accident

PTSD (post-traumatic stress disorder) affects approximately 39% of motor vehicle accident survivors to some degree, with full diagnostic PTSD criteria met in roughly 8-15% of cases. The condition develops when the traumatic experience of an accident produces persistent re-experiencing (flashbacks, nightmares), avoidance of trauma-related stimuli (reluctance to drive, anxiety in vehicles), negative alterations in cognition and mood, and hyperarousal (startling easily, sleep problems, irritability).

For personal injury patients, PTSD is not a secondary or collateral complaint — it is a direct psychological consequence of the accident, as causally linked to the event as a broken bone or herniated disc.

Rexulti (Brexpiprazole) for PTSD

In May 2023, the FDA approved brexpiprazole as an adjunctive treatment for PTSD in adults — a significant regulatory milestone because it was the first new FDA approval specifically for PTSD in over 20 years. Rexulti (brexpiprazole) joins a short list of drugs with specific PTSD indications.

Mechanism: Brexpiprazole is an atypical antipsychotic that functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors. This receptor profile is distinct from the SSRIs (sertraline, paroxetine) that are the existing first-line PTSD pharmacotherapy and explains why brexpiprazole can provide additional benefit when added to an SSRI.

Indication: Adjunctive treatment for PTSD — meaning it is added to existing SSRI therapy, not used as a standalone. The clinical paradigm is: SSRI (sertraline or paroxetine) for core PTSD symptoms + Rexulti for residual symptoms that don't fully respond.

Dosing: 0.5mg daily, titrated to 1mg daily and then potentially 2mg daily based on response and tolerability.

Why it matters for PI: A personal injury patient prescribed Rexulti has received a formal psychiatric diagnosis of PTSD (or PTSD-spectrum disorder) and has shown inadequate response to first-line SSRI monotherapy. The adjunctive prescription documents the severity and treatment-refractoriness of the PTSD condition, substantially strengthening the psychological injury component of the claim.

[!KEY] Rexulti is the first FDA-approved PTSD drug in over 20 years — its prescription documents not just a PTSD diagnosis but a PTSD case severe enough that SSRI monotherapy was insufficient, which is the strongest available pharmacy-record signal of clinically significant post-traumatic psychiatric injury.

Brand-name only: Brexpiprazole is available only as Rexulti. There is no generic equivalent.

Sleep Disruption After Personal Injury

Sleep disruption after a personal injury is not simply a symptom of discomfort — it is a physiologically distinct condition that requires targeted treatment and that, when untreated, perpetuates and worsens pain, cognitive function, and emotional regulation.

The biology is well-established: pain and hyperarousal (a hallmark of PTSD and anxiety) suppress slow-wave sleep and REM sleep, pushing patients into lighter sleep stages where restorative processes cannot occur. This sleep deprivation then lowers pain tolerance (because adequate sleep is required to maintain the brain's endogenous pain inhibitory systems), creating a vicious cycle in which pain disrupts sleep and poor sleep amplifies pain.

Clinical significance for PI cases: A patient who cannot sleep because of injury-related pain has a documentable functional impairment. A sleep medication prescription is not incidental — it reflects a physician's clinical determination that sleep disruption is significant enough to require pharmacological intervention.

Quviviq (Daridorexant)

FDA-approved in January 2022, daridorexant represents the newest class of sleep medications. Rather than the older approach of sedating the brain with GABA-enhancing agents (benzodiazepines, Z-drugs), daridorexant works by blocking orexin — a wake-promoting neuropeptide.

Mechanism: Orexin (also called hypocretin) is produced in the hypothalamus and drives wakefulness by activating arousal centers throughout the brain. Blocking orexin signaling reduces the drive to stay awake, allowing natural sleep mechanisms to take over. This is fundamentally different from sedation — it does not induce unconsciousness, it removes the neurochemical pressure keeping the patient awake.

Why this matters: Patients with injury-related hyperarousal and pain have elevated orexin signaling — their brains are receiving excessive wake-promoting signals even when their bodies need sleep. Daridorexant specifically addresses this dysregulation.

Dosing: 25mg or 50mg taken within 30 minutes before bed.

Clinical advantages: Quviviq does not cause next-day cognitive impairment in the way that older sedative sleep medications do — clinical trials demonstrated no significant impairment on driving simulations the morning after. For PI patients who need to drive to medical appointments, attend depositions, or maintain employment, this is a meaningful clinical consideration.

[!KEY] A physician who prescribes Quviviq or Dayvigo instead of an older sedative has documented that the patient's sleep disorder requires mechanism-targeted treatment — the DORA prescription also tells a specific clinical story that the patient's insomnia is driven by hyperarousal from pain or PTSD rather than simple difficulty relaxing.

Brand-name only: Daridorexant is available only as Quviviq.

Dayvigo (Lemborexant)

FDA-approved in December 2019, lemborexant was the first dual orexin receptor antagonist (DORA) approved in the United States, preceding daridorexant. It shares the same mechanistic class — blocking orexin to reduce wake drive — with some pharmacological differences in receptor selectivity and pharmacokinetics.

Dosing: 5mg or 10mg taken immediately before bed.

Clinical profile: Lemborexant has demonstrated efficacy for sleep onset latency (time to fall asleep) and sleep maintenance (staying asleep through the night) — both of which are commonly disrupted in injury-related sleep disorders. The 10mg dose provides more robust sleep maintenance effects relevant to patients who wake repeatedly due to pain.

For PI patients: Dayvigo's profile is particularly relevant for injury patients whose sleep disruption is characterized by frequent nighttime awakenings due to positional pain — a common complaint in patients with back injuries, shoulder injuries, and cervical injuries.

Brand-name only: Lemborexant is available only as Dayvigo.

Why PTSD and Sleep Medications Belong in a PI Lien

Documenting the Psychological Dimension of Injury

Personal injury cases that include documented PTSD are associated with significantly higher settlement values, because psychological injury is a recognized component of compensable harm. Medications prescribed specifically for PTSD — particularly a drug with a 2023 FDA PTSD indication like Rexulti — provide prescription-level documentation of the psychiatric diagnosis.

Sleep Disruption as Functional Impairment

An inability to achieve restorative sleep is a functional impairment that affects the patient's capacity to work, maintain concentration, manage relationships, and participate in rehabilitation. Physicians who prescribe Quviviq or Dayvigo have made a clinical determination that the patient's sleep disruption is significant enough to require pharmacological intervention — documentation that supports a broader damages claim.

These Are Not Benzodiazepines

Defense attorneys frequently challenge sedative prescriptions as inappropriate or dependency-seeking. Neither Rexulti, Quviviq, nor Dayvigo is a controlled substance. They work through non-sedative mechanisms (orexin blockade for sleep, dopamine/serotonin modulation for PTSD) that are well-accepted and evidence-based. There is no controlled substance narrative for opposing counsel to exploit.

Combination with Pain Medications

PTSD and sleep medications are virtually always prescribed alongside physical injury medications — they do not replace pain management, they address the psychiatric and sleep dimensions simultaneously. A client on five medications for physical injury, plus Rexulti and Quviviq, has a comprehensive documented treatment picture reflecting the full biopsychosocial impact of the accident.

[!KEY] A client on physical injury medications plus Rexulti (PTSD) and Quviviq or Dayvigo (sleep) has a pharmacy record documenting the full biopsychosocial impact of the accident — physical pain, psychiatric sequelae, and functional sleep impairment all independently documented, each supporting a distinct category of compensable harm.

What Attorneys Should Know

Rexulti: Signals a PTSD diagnosis of sufficient severity to require adjunctive pharmacotherapy beyond SSRI monotherapy. Consult your client's psychiatric records to understand the full diagnostic picture.

Quviviq / Dayvigo: Signal documented sleep disorder significant enough for a physician to prescribe orexin-targeted therapy. Ask about sleep diary documentation or sleep study records, which may accompany prescriptions for these agents.

Duration: PTSD and chronic sleep disorders often require sustained pharmacotherapy over 6-18+ months. Extended treatment periods create correspondingly extended documentation trails.

Conclusion

PTSD and sleep disruption are common, clinically significant, and increasingly well-documented consequences of personal injury accidents. The medications available to treat them — Rexulti for PTSD, Quviviq and Dayvigo for sleep — are brand-name, non-controlled, evidence-based therapies that belong in comprehensive PI lien coverage.

For lien-based pharmacy coverage of psychiatric and sleep medications following a personal injury, LienScripts provides pharmacy services for PI patients with no upfront cost and repayment from settlement proceeds.

Related Resources

• Why PI Patients Often Need Multiple Medications
• PTSD After a Personal Injury Accident: Medications and Treatment
• Sleep Disorders After Trauma: Why Accident Victims Can't Sleep
• Sertraline After an Accident: Treating PTSD and Depression